Skip to content

About us

eCounsel group

A boutique firm with unparalleled expertise in business and technology. We have good command of industrial ecology and legal practice, and have undertaken highly regarded cases. Because the small business scope, we pay more emphasis on effectiveness and efficiency, and choose clients with deliberation. The managing partner not only has extensive experiences in various legal issues more over than 20 years, but invests and manages several technology companies. In addition, he always checks each case rigorously. Clients’ business objectives are our primary focus. To achieve the same in the most cost-effective fashion trumps all seemingly sophisticated legal discussions.

Drug Prices in Taiwan Are Too Low

2016 - 10 - 28

In U.S, there usually is a co-payment charged at the pharmacies for most prescription drugs. Even for one or two generic drugs, you are paying tens of dollars.


美國人看醫生拿處方箋,到藥局領藥多半都有自負額 (co-payment),而且金額還不低;一次門診即便只是開給你普通的學名藥一兩種,進了藥局都得噴掉幾十鎂,萬一是仍在專利期內的原廠藥或罕病藥就更別提了。所以,真的有不少窮老美在看完醫生、確認完藥價後,就低頭抱病回家養病了;畢竟如果真的掏錢買藥,小孩就會沒飯吃、繳不起學費啊!

更讓他們憤怒的是,藥價居然還年年漲!一年平均漲11%(從2011起)!
Brand-name drug prices rose an average just over 11% a year from 2011 to 2015

本所之前的文章,批判台灣一手玩藥價調查(逼藥廠降價)、另一手讓病人拿藥幾近免費(門診藥費自負額上限NT$200),這是助長藥物濫取健保負擔沈重的元凶。

醫、藥,都是救人命的,搞不好也是會出人命的。對專業欠缺基本尊重,是台灣健保的問題;對病人冷血地予取予求,是美國制度的問題。

唉,過猶不及啊。

新聞來源:
What’s Happening With Drug Prices?

Recommended article 

Lack of Knowledge in Law, A Cog Could Break The Machine

We have been the legal counsel for the company for a decade. It is a listed company in Taiwan, has a healthy growth in sales and EPS year over year and its stock price looks great.…

So Much for Donald Trump

If you have been following U.S presidential election like us, you could probably tell: The winning chance for Donald Trump is practically zero. Continue reading

Internal Data not Accessible and Bad Executions

According to the “Code of Internal Controls System Establishment for Public Traded Companies”: Public traded companies should review the effectiveness of its internal controls system annually. 根據「公開發行公司建立內部控制制度處理準則」之規定1,公開發行公司應該每年自行檢查內部控制制度執行的有效性,內容必須涵蓋所有的內部控制制度,同時公司本身要訂出一套內部控制制度自行檢查作業之程序與方法,將檢查結果製作成內部控制聲明書之後呈報主管機關備查。 根據實證研究報告所蒐集之問卷指出2,在這個「內控自評」之過程當中,內部稽核單位會遇到的困難除了前述所提及的人力不足、資源有限之外,還會出現公司內部機密資料不易取得、資訊運用欠缺的問題。 讀者或許會納悶,公司內部的稽核部門,或是其他部門如業務、行銷部門既然都同屬一家公司,理應容易取得其他部門的資料才是,又為何會有此種所謂「內部機密資料不易取得」而無法稽核的情況呢? 事實上,不難想像在一家頗有規模的公開發行公司當中,各個部門各司其職,而且在資料的管理上也是分由各種不同部門負責,而通常內部稽核部門因其職責所在,容易被其他部門視為找麻煩的部門,如果內部稽核部門不受到管理階級如總經理、董事長的大力支持的話,其他部門當然不會願意提供稽核部門真正所需要的資料,畢竟,沒有人會願意自接瘡疤的。 如果沒有相關的業務資料及文件,也會造成內部稽核人員的工作內容無法受到監督,內部稽核單位的工作是監督、查核各單位的業務,而內部稽核人員本身也必須受到董事會的的監督3,但是如果內部稽核人員所繳交的稽核報告當中都沒有各業務單位的原始資料、證據,董事會根本無法監督其工作內容,內部稽核單位有沒有認真執行任務不得而知。 如此一來,得不到應有的資料根本無法確實稽核相關業務,也無法再被董事會監督4,內部稽核報告內未附工作底稿及相關資料是一個實務上常見的缺失,必須受到企業經營者的重視。 1. 請參「公開發行公司建立內部控制制度處理準則」第22 條。 2.…